




S1




Lane 1




Lane 3




Lane 5









HMGCR Exon 13 Exclusion/Inclusion























LDLR Exon 4 Exclusion/Inclusion











S3






























































































































































(A) Distribution of Protein Coding Gene FPKMs(B) Distribution of Pharmacogene FPKMs(C) Distribution of Protein Coding Gene FPKMs(D) Distribution of Pharmacogene FPKMs






S5A

All Protein Coding Genes




S5B


Pharmacogenes




A






B




C




A**B**





S10



Supplemental Table S1. List of 389 pharmacogenes and their categories based on their functions. Annotation for drug target is compiled from Rask-Anderson, M et al. The druggable genome: Evaluation of drug targets in clinical trials suggests major shifts in molecular class and indication. *Annu Rev Pharmacol Toxicol.* 54, 9-26 (2014).

| Number | Gene | Ensembl Gene ID | Category | Drug Target | GPCR as Drug Target | Enzyme as Drug Target | Ion Channel as Drug Target |
|--------|------------|--------------------|------------------|-------------|---------------------|-----------------------|----------------------------|
| 1 | ABCA1 | ENSG00000165029.11 | ABC_Transporter | N | N | N | N |
| 2 | ABCA4 | ENSG00000198691.6 | ABC_Transporter | Y | N | N | N |
| 3 | ABCB1 | ENSG00000085563.8 | ABC_Transporter | Y | N | N | N |
| 4 | ABCB10 | ENSG00000135776.4 | ABC_Transporter | N | N | N | N |
| 5 | ABCB11 | ENSG00000073734.8 | ABC_Transporter | N | N | N | N |
| 6 | ABCB4 | ENSG00000005471.11 | ABC_Transporter | N | N | N | N |
| 7 | ABCB5 | ENSG00000004846.12 | ABC_Transporter | N | N | N | N |
| 8 | ABCB6 | ENSG00000115657.7 | ABC_Transporter | N | N | N | N |
| 9 | ABCB7 | ENSG00000131269.10 | ABC_Transporter | N | N | N | N |
| 10 | ABCB8 | ENSG00000197150.7 | ABC_Transporter | N | N | N | N |
| 11 | ABCB9 | ENSG00000150967.12 | ABC_Transporter | N | N | N | N |
| 12 | ABCC1 | ENSG00000103222.13 | ABC_Transporter | Y | N | N | N |
| 13 | ABCC10 | ENSG00000124574.9 | ABC_Transporter | N | N | N | N |
| 14 | ABCC12 | ENSG00000140798.10 | ABC_Transporter | N | N | N | N |
| 15 | ABCC2 | ENSG00000023839.6 | ABC_Transporter | Y | N | N | N |
| 16 | ABCC3 | ENSG00000108846.11 | ABC_Transporter | N | N | N | N |
| 17 | ABCC4 | ENSG00000125257.9 | ABC_Transporter | N | N | N | N |
| 18 | ABCC5 | ENSG00000114770.11 | ABC_Transporter | N | N | N | N |
| 19 | ABCC6 | ENSG00000091262.9 | ABC_Transporter | N | N | N | N |
| 20 | ABCC8 | ENSG00000006071.6 | ABC_Transporter | Y | N | N | N |
| 21 | ABCC9 | ENSG00000069431.6 | ABC_Transporter | N | N | N | N |
| 22 | ABCG2 | ENSG00000118777.6 | ABC_Transporter | N | N | N | N |
| 23 | ABCG8 | ENSG00000143921.6 | ABC_Transporter | N | N | N | N |
| 24 | ABP1 | ENSG00000002726.14 | Other_Metabolism | N | N | N | N |
| 25 | AC008537.2 | ENSG00000256612.1 | Other | N | N | N | N |
| 26 | ACE | ENSG00000159640.8 | Other | Y | N | Y | N |
| 27 | ADD1 | ENSG00000087274.11 | Other | N | N | N | N |
| 28 | ADH1A | ENSG00000187758.3 | ADH_Metabolism | Y | N | Y | N |
| 29 | ADH1B | ENSG00000196616.7 | ADH_Metabolism | Y | N | Y | N |
| 30 | ADH1C | ENSG00000248144.1 | ADH_Metabolism | Y | N | Y | N |
| 31 | ADH4 | ENSG00000198099.4 | ADH_Metabolism | N | N | Y | N |
| 32 | ADH5 | ENSG00000197894.6 | ADH_Metabolism | N | N | Y | N |
| 33 | ADH6 | ENSG00000172955.13 | ADH_Metabolism | N | N | Y | N |
| 34 | ADH7 | ENSG00000196344.7 | ADH_Metabolism | N | N | Y | N |
| 35 | ADRA1B | ENSG00000170214.3 | Receptor | Y | Y | N | N |
| 36 | ADRA2C | ENSG00000184160.6 | Receptor | Y | Y | N | N |
| 37 | ADRB1 | ENSG00000043591.4 | Receptor | Y | Y | N | N |

| | | | | | | | |
|----|---------|--------------------|--|---|---|---|---|
| 38 | ADRB2 | ENSG00000169252.4 | Receptor | Y | Y | N | N |
| 39 | ADRB3 | ENSG00000188778.3 | Receptor | Y | Y | N | N |
| 40 | AGTR1 | ENSG00000144891.13 | Receptor Nuclear | Y | Y | N | N |
| 41 | AHR | ENSG00000106546.8 | Receptor/Transcripti on Factor | N | N | N | N |
| 42 | AKAP9 | ENSG00000127914.11 | Other | N | N | N | N |
| 43 | ALB | ENSG00000163631.11 | Other | N | N | N | N |
| 44 | ALDH1A1 | ENSG00000165092.7 | ALDH_Metabolism | N | N | Y | N |
| 45 | ALDH2 | ENSG00000111275.6 | ALDH_Metabolism | Y | N | Y | N |
| 46 | ALDH3A1 | ENSG00000108602.12 | ALDH_Metabolism | N | N | Y | N |
| 47 | ALDH3A2 | ENSG00000072210.12 | ALDH_Metabolism | N | N | Y | N |
| 48 | ALDH4A1 | ENSG00000159423.11 | ALDH_Metabolism | N | N | Y | N |
| 49 | ALDH5A1 | ENSG00000112294.8 | ALDH_Metabolism | N | N | Y | N |
| 50 | ALDH6A1 | ENSG00000119711.8 | ALDH_Metabolism | N | N | Y | N |
| 51 | ALOX5 | ENSG00000012779.5 | Other | Y | N | N | N |
| 52 | AOX1 | ENSG00000138356.9 | Other_Metabolism | N | N | N | N |
| 53 | APOA1 | ENSG00000118137.5 | Other | Y | N | N | N |
| 54 | APOA2 | ENSG00000158874.6 | Other | N | N | N | N |
| 55 | APOA4 | ENSG00000110244.5 | Other | N | N | N | N |
| 56 | APOB | ENSG00000084674.8 | Other | Y | N | N | N |
| 57 | APOE | ENSG00000130203.4 | Other | N | N | N | N |
| 58 | ARID5B | ENSG00000150347.10 | Other Nuclear | N | N | N | N |
| 59 | ARNT | ENSG00000143437.14 | Receptor/Transcripti on Factor | N | N | N | N |
| 60 | ARSA | ENSG00000100299.12 | Other | N | N | N | N |
| 61 | ATP7A | ENSG00000165240.12 | Other_Transporter | N | N | N | N |
| 62 | ATP7B | ENSG00000123191.9 | Other_Transporter | N | N | N | N |
| 63 | BDKRB2 | ENSG00000168398.5 | Receptor | Y | Y | N | N |
| 64 | BDNF | ENSG00000176697.12 | Other | N | N | N | N |
| 65 | BRCA1 | ENSG00000012048.13 | Other | N | N | N | N |
| 66 | BRCA2 | ENSG00000139618.9 | Other | N | N | N | N |
| 67 | CACNA1C | ENSG00000151067.14 | Channel | Y | N | N | Y |
| 68 | CACNA1S | ENSG00000081248.6 | Channel | Y | N | N | Y |
| 69 | CACNB2 | ENSG00000165995.14 | Channel | Y | N | N | Y |
| 70 | CBR1 | ENSG00000159228.8 | Other_Metabolism | N | N | N | N |
| 71 | CBR3 | ENSG00000159231.5 | Other_Metabolism | N | N | N | N |
| 72 | CCDC101 | ENSG00000176476.4 | Other | N | N | N | N |
| 73 | CCND1 | ENSG00000110092.2 | Other | Y | N | N | N |
| 74 | CDA | ENSG00000158825.5 | Other_Metabolism Nuclear | N | N | N | N |
| 75 | CEBPA | ENSG00000245848.2 | Receptor/Transcripti on Factor Nuclear | N | N | N | N |
| 76 | CEBPB | ENSG00000172216.4 | Receptor/Transcripti on Factor | N | N | N | N |

| | | | | | | | |
|-----|---------|--------------------|------------------|---|---|---|---|
| 77 | CES1 | ENSG00000198848.7 | Other_Metabolism | N | N | N | N |
| 78 | CES2 | ENSG00000172831.6 | Other_Metabolism | N | N | N | N |
| 79 | CETP | ENSG00000087237.6 | Other | Y | N | N | N |
| 80 | CFTR | ENSG00000001626 | ABC_Transporter | Y | Y | N | N |
| 81 | CHRM3 | ENSG00000133019.7 | Receptor | Y | Y | N | N |
| 82 | CHST1 | ENSG00000175264.3 | Other | N | N | N | N |
| 83 | CHST10 | ENSG00000115526.6 | Other | N | N | N | N |
| 84 | CHST11 | ENSG00000171310.6 | Other | N | N | N | N |
| 85 | CHST13 | ENSG00000180767.4 | Other | N | N | N | N |
| 86 | CHST2 | ENSG00000175040.4 | Other | N | N | N | N |
| 87 | CHST3 | ENSG00000122863.5 | Other | N | N | N | N |
| 88 | CHST4 | ENSG00000140835.7 | Other | N | N | N | N |
| 89 | CHST5 | ENSG00000135702.10 | Other | N | N | N | N |
| 90 | CHST6 | ENSG00000183196.4 | Other | N | N | N | N |
| 91 | CHST7 | ENSG00000147119.3 | Other | N | N | N | N |
| 92 | CHST8 | ENSG00000124302.5 | Other | N | N | N | N |
| 93 | CHST9 | ENSG00000154080.7 | Other | N | N | N | N |
| 94 | COL1A1 | ENSG00000108821.8 | Other | Y | N | N | N |
| 95 | COMT | ENSG00000093010.7 | Other_Metabolism | Y | N | Y | N |
| 96 | CR1 | ENSG00000203710.5 | Receptor | N | N | N | N |
| 97 | CRHR1 | ENSG00000120088.9 | Receptor | Y | Y | N | N |
| 98 | CROT | ENSG00000005469.7 | Other | Y | N | N | N |
| 99 | CYB5A | ENSG00000166347.12 | Other_Metabolism | N | N | N | N |
| 100 | CYB5B | ENSG00000103018.11 | Other_Metabolism | N | N | N | N |
| 101 | CYB5R3 | ENSG00000100243.15 | Other_Metabolism | N | N | N | N |
| 102 | CYP11A1 | ENSG00000140459.11 | CYP_Metabolism | N | N | N | N |
| 103 | CYP11B1 | ENSG00000160882.7 | CYP_Metabolism | Y | N | Y | N |
| 104 | CYP11B2 | ENSG00000179142.2 | CYP_Metabolism | N | N | N | N |
| 105 | CYP17A1 | ENSG00000148795.4 | CYP_Metabolism | Y | N | Y | N |
| 106 | CYP19A1 | ENSG00000137869.8 | CYP_Metabolism | Y | N | Y | N |
| 107 | CYP1A1 | ENSG00000140465.8 | CYP_Metabolism | N | N | N | N |
| 108 | CYP1A2 | ENSG00000140505.6 | CYP_Metabolism | N | N | N | N |
| 109 | CYP1B1 | ENSG00000138061.7 | CYP_Metabolism | Y | N | Y | N |
| 110 | CYP20A1 | ENSG00000119004.9 | CYP_Metabolism | N | N | N | N |
| 111 | CYP21A2 | ENSG00000231852.2 | CYP_Metabolism | N | N | N | N |
| 112 | CYP24A1 | ENSG00000019186.5 | CYP_Metabolism | Y | N | Y | N |
| 113 | CYP26A1 | ENSG00000095596.7 | CYP_Metabolism | Y | N | Y | N |
| 114 | CYP26C1 | ENSG00000187553.5 | CYP_Metabolism | Y | N | Y | N |
| 115 | CYP27A1 | ENSG00000135929.4 | CYP_Metabolism | N | N | N | N |
| 116 | CYP27B1 | ENSG00000111012.4 | CYP_Metabolism | N | N | N | N |
| 117 | CYP2A13 | ENSG00000197838.3 | CYP_Metabolism | N | N | N | N |
| 118 | CYP2A6 | ENSG00000255974.1 | CYP_Metabolism | N | N | N | N |
| 119 | CYP2A7 | ENSG00000198077.5 | CYP_Metabolism | N | N | N | N |

| | | | | | | | |
|-----|---------|--------------------|------------------|---|---|---|---|
| 120 | CYP2B6 | ENSG00000197408.3 | CYP_Metabolism | N | N | N | N |
| 121 | CYP2C18 | ENSG00000108242.7 | CYP_Metabolism | N | N | N | N |
| 122 | CYP2C19 | ENSG00000165841.5 | CYP_Metabolism | N | N | N | N |
| 123 | CYP2C8 | ENSG00000138115.7 | CYP_Metabolism | N | N | N | N |
| 124 | CYP2C9 | ENSG00000138109.8 | CYP_Metabolism | N | N | N | N |
| 125 | CYP2D6 | ENSG00000100197.15 | CYP_Metabolism | N | N | N | N |
| 126 | CYP2E1 | ENSG00000130649.5 | CYP_Metabolism | N | N | N | N |
| 127 | CYP2F1 | ENSG00000197446.3 | CYP_Metabolism | N | N | N | N |
| 128 | CYP2J2 | ENSG00000134716.5 | CYP_Metabolism | N | N | N | N |
| 129 | CYP2R1 | ENSG00000186104.6 | CYP_Metabolism | N | N | N | N |
| 130 | CYP2S1 | ENSG00000167600.7 | CYP_Metabolism | N | N | N | N |
| 131 | CYP3A1 | ENSG00000146233.3 | CYP_Metabolism | N | N | N | N |
| 132 | CYP3A4 | ENSG00000160868.9 | CYP_Metabolism | Y | N | Y | N |
| 133 | CYP3A43 | ENSG00000021461.11 | CYP_Metabolism | N | N | N | N |
| 134 | CYP3A5 | ENSG00000106258.9 | CYP_Metabolism | Y | N | Y | N |
| 135 | CYP3A7 | ENSG00000160870.7 | CYP_Metabolism | Y | N | Y | N |
| 136 | CYP4A1 | ENSG00000036530.4 | CYP_Metabolism | Y | N | Y | N |
| 137 | CYP4A11 | ENSG00000187048.8 | CYP_Metabolism | N | N | N | N |
| 138 | CYP4B1 | ENSG00000142973.8 | CYP_Metabolism | N | N | N | N |
| 139 | CYP4F11 | ENSG00000171903.10 | CYP_Metabolism | N | N | N | N |
| 140 | CYP4F12 | ENSG00000186204.8 | CYP_Metabolism | N | N | N | N |
| 141 | CYP4F2 | ENSG00000186115.5 | CYP_Metabolism | N | N | N | N |
| 142 | CYP4F3 | ENSG00000186529.7 | CYP_Metabolism | N | N | N | N |
| 143 | CYP4F8 | ENSG00000186526.6 | CYP_Metabolism | N | N | N | N |
| 144 | CYP4Z1 | ENSG00000186160.4 | CYP_Metabolism | N | N | N | N |
| 145 | CYP51A1 | ENSG00000001630.10 | CYP_Metabolism | N | N | N | N |
| 146 | CYP7A1 | ENSG00000167910.3 | CYP_Metabolism | N | N | N | N |
| 147 | CYP7B1 | ENSG00000172817.3 | CYP_Metabolism | N | N | N | N |
| 148 | CYP8B1 | ENSG00000180432.4 | CYP_Metabolism | N | N | N | N |
| 149 | DBH | ENSG00000123454.5 | Other_Metabolism | Y | N | Y | N |
| 150 | DCK | ENSG00000156136.5 | Other_Metabolism | Y | N | Y | N |
| 151 | DHFR | ENSG000000228716.2 | Other_Metabolism | Y | N | Y | N |
| 152 | DPYD | ENSG00000188641.8 | Other_Metabolism | Y | N | Y | N |
| 153 | DRD1 | ENSG00000184845.2 | Receptor | Y | Y | N | N |
| 154 | DRD2 | ENSG00000149295.9 | Receptor | Y | Y | N | N |
| 155 | DRD3 | ENSG00000151577.6 | Receptor | Y | Y | N | N |
| 156 | DRD4 | ENSG00000069696.6 | Receptor | Y | Y | N | N |
| 157 | DRD5 | ENSG00000169676.4 | Receptor | Y | Y | N | N |
| 158 | EGFR | ENSG00000146648.10 | Receptor | Y | N | N | N |
| 159 | EPHX1 | ENSG00000143819.8 | Other_Metabolism | Y | N | Y | N |
| 160 | EPHX2 | ENSG00000120915.8 | Other_Metabolism | Y | N | Y | N |
| 161 | ESR1 | ENSG00000091831.15 | Receptor | Y | N | N | N |
| 162 | ESR2 | ENSG00000140009.14 | Receptor | Y | N | N | N |

| | | | | | | | |
|-----|--------|--------------------|--|---|---|---|---|
| 163 | F2 | ENSG00000180210.9 | Other | Y | N | N | N |
| 164 | F5 | ENSG00000198734.6 | Other | Y | N | N | N |
| 165 | FAAH | ENSG00000117480.10 | Other_Metabolism | Y | N | Y | N |
| 166 | FCGR2A | ENSG00000143226.8 | Receptor | N | N | N | N |
| 167 | FCGR3A | ENSG00000203747.5 | Receptor | N | N | N | N |
| 168 | FKBP5 | ENSG00000096060.8 | Other | N | N | N | N |
| 169 | FMO1 | ENSG00000010932.11 | Other_Metabolism | N | N | N | N |
| 170 | FMO2 | ENSG00000094963.9 | Other_Metabolism | N | N | N | N |
| 171 | FMO3 | ENSG00000007933.8 | Other_Metabolism | N | N | N | N |
| 172 | FMO4 | ENSG00000076258.5 | Other_Metabolism | N | N | N | N |
| 173 | FMO5 | ENSG00000131781.8 | Other_Metabolism | N | N | N | N |
| 174 | FMO6P | ENSG00000117507.3 | Other_Metabolism | N | N | N | N |
| 175 | FOXA3 | ENSG00000170608.1 | Nuclear Receptor/Transcripti on Factor | N | N | N | N |
| 176 | G6PD | ENSG00000160211.10 | Other_Metabolism | N | N | N | N |
| 177 | GLCCI1 | ENSG00000106415.8 | Other | N | N | N | N |
| 178 | GNB3 | ENSG00000111664.6 | Other | N | N | N | N |
| 179 | GPX7 | ENSG00000116157.5 | Other_Metabolism | N | N | N | N |
| 180 | GRK4 | ENSG00000125388.14 | Other | N | N | N | N |
| 181 | GRK5 | ENSG00000198873.8 | Other | N | N | N | N |
| 182 | GRM3 | ENSG00000198822.6 | Receptor | Y | Y | N | N |
| 183 | GSR | ENSG00000104687.8 | Other_Metabolism | Y | N | Y | N |
| 184 | GSTA1 | ENSG00000243955.1 | GST_Metabolism | N | N | N | N |
| 185 | GSTA2 | ENSG00000244067.1 | GST_Metabolism | N | N | N | N |
| 186 | GSTA3 | ENSG00000174156.7 | GST_Metabolism | N | N | N | N |
| 187 | GSTA4 | ENSG00000170899.6 | GST_Metabolism | N | N | N | N |
| 188 | GSTA5 | ENSG00000182793.5 | GST_Metabolism | N | N | N | N |
| 189 | GSTK1 | ENSG00000197448.9 | GST_Metabolism | N | N | N | N |
| 190 | GSTM1 | ENSG00000134184.7 | GST_Metabolism | N | N | N | N |
| 191 | GSTM2 | ENSG00000213366.6 | GST_Metabolism | N | N | N | N |
| 192 | GSTM3 | ENSG00000134202.6 | GST_Metabolism | N | N | N | N |
| 193 | GSTM4 | ENSG00000168765.10 | GST_Metabolism | N | N | N | N |
| 194 | GSTM5 | ENSG00000134201.5 | GST_Metabolism | N | N | N | N |
| 195 | GSTO1 | ENSG00000148834.8 | GST_Metabolism | N | N | N | N |
| 196 | GSTO2 | ENSG00000065621.8 | GST_Metabolism | N | N | N | N |
| 197 | GSTP1 | ENSG00000084207.11 | GST_Metabolism | Y | N | Y | N |
| 198 | GSTT1 | ENSG00000184674.7 | GST_Metabolism | N | N | N | N |
| 199 | GSTT2 | ENSG00000099984.6 | GST_Metabolism | N | N | N | N |
| 200 | GSTZ1 | ENSG00000100577.14 | GST_Metabolism | N | N | N | N |
| 201 | HLA-B | ENSG00000234745.3 | Other | N | N | N | N |
| 202 | HMGCR | ENSG00000113161.10 | Other | Y | N | N | N |
| 203 | HNF1A | ENSG00000135100.9 | Nuclear Receptor/Transcripti on Factor | N | N | N | N |

| | | | | | | | |
|-----|---------|--------------------|--|---|---|---|---|
| 204 | HNF4A | ENSG00000101076.10 | Nuclear Receptor/Transcripti on Factor | N | N | N | N |
| 205 | HNMT | ENSG00000150540.9 | Other_Metabolism | N | N | N | N |
| 206 | HSD11B2 | ENSG00000176387.5 | Other_Metabolism | N | N | N | N |
| 207 | HTR1A | ENSG00000178394.3 | Receptor | Y | Y | N | N |
| 208 | HTR2A | ENSG00000102468.5 | Receptor | Y | Y | N | N |
| 209 | IL10 | ENSG00000136634.5 | Other | N | N | N | N |
| 210 | IL1B | ENSG00000125538.7 | Other | Y | N | N | N |
| 211 | IL28B | ENSG00000197110 | Other | N | N | N | N |
| 212 | INPP1 | ENSG00000151689.8 | Other | N | N | N | N |
| 213 | JUN | ENSG00000177606.5 | Nuclear Receptor/Transcripti on Factor | Y | N | N | N |
| 214 | KCNE1 | ENSG00000180509.7 | Channel | Y | N | N | Y |
| 215 | KCNE2 | ENSG00000159197.2 | Channel | N | N | N | N |
| 216 | KCNH2 | ENSG00000055118.9 | Channel | Y | N | N | Y |
| 217 | KCNJ11 | ENSG00000187486.5 | Channel | Y | N | N | Y |
| 218 | KCNQ1 | ENSG00000053918.10 | Channel | Y | N | N | Y |
| 219 | LDLR | ENSG00000130164.6 | Receptor | N | N | N | N |
| 220 | LPL | ENSG00000175445.9 | Other | Y | N | N | N |
| 221 | LTC4S | ENSG00000213316.5 | Other | N | N | N | N |
| 222 | MAOA | ENSG00000189221.5 | Other_Metabolism | Y | N | Y | N |
| 223 | MAOB | ENSG00000069535.11 | Other_Metabolism | Y | N | Y | N |
| 224 | MAT1A | ENSG00000151224.7 | Other | N | N | N | N |
| 225 | METTL1 | ENSG00000037897.12 | Other | N | N | N | N |
| 226 | MLH1 | ENSG00000076242.9 | Other | N | N | N | N |
| 227 | MMP3 | ENSG00000149968.7 | Other | Y | N | N | N |
| 228 | MTHFR | ENSG00000177000.6 | Other_Metabolism | N | N | N | N |
| 229 | NAT1 | ENSG00000171428.9 | Other_Metabolism | N | N | N | N |
| 230 | NAT2 | ENSG00000156006.4 | Other_Metabolism | N | N | N | N |
| 231 | NCOR1 | ENSG00000141027.13 | Nuclear Receptor/Transcripti on Factor | N | N | N | N |
| 232 | NNMT | ENSG00000166741.3 | Other_Metabolism | Y | N | Y | N |
| 233 | NOS3 | ENSG00000164867.5 | Other_Metabolism | Y | N | Y | N |
| 234 | NPPB | ENSG00000120937.7 | Other | N | N | N | N |
| 235 | NPR1 | ENSG00000169418.7 | Receptor | Y | Y | N | N |
| 236 | NQO1 | ENSG00000181019.8 | Other_Metabolism | Y | N | Y | N |
| 237 | NQO2 | ENSG00000124588.13 | Other_Metabolism | Y | N | Y | N |
| 238 | NR0B2 | ENSG00000131910.4 | Nuclear Receptor/Transcripti on Factor | N | N | N | N |
| 239 | NR1H2 | ENSG00000131408.7 | Nuclear Receptor/Transcripti on Factor | N | N | N | N |
| 240 | NR1H3 | ENSG00000025434.14 | Nuclear Receptor/Transcripti on Factor | N | N | N | N |

| | | | | | | | |
|-----|----------|--------------------|--|---|---|---|---|
| 241 | NR1H4 | ENSG00000012504.9 | Nuclear Receptor/Transcripti on Factor | Y | N | N | N |
| 242 | NR1I2 | ENSG00000144852.12 | Nuclear Receptor/Transcripti on Factor | N | N | N | N |
| 243 | NR1I3 | ENSG00000143257.7 | Nuclear Receptor/Transcripti on Factor | N | N | N | N |
| 244 | NR3C1 | ENSG00000113580.9 | Nuclear Receptor/Transcripti on Factor | Y | N | N | N |
| 245 | NR3C2 | ENSG00000151623.9 | Nuclear Receptor/Transcripti on Factor | Y | N | N | N |
| 246 | OPRM1 | ENSG00000112038.12 | Receptor | Y | Y | N | N |
| 247 | ORM1 | ENSG00000229314.4 | Other | N | N | N | N |
| 248 | ORM2 | ENSG00000228278.2 | Other | N | N | N | N |
| 249 | P2RY1 | ENSG00000169860.4 | Receptor | Y | Y | N | N |
| 250 | P2RY12 | ENSG00000169313.8 | Receptor | Y | Y | N | N |
| 251 | PARK2 | ENSG00000185345.13 | Other | N | N | N | N |
| 252 | PEAR1 | ENSG00000187800.9 | Receptor | N | N | N | N |
| 253 | PGAP3 | ENSG00000161395.7 | Other | N | N | N | N |
| 254 | PNMT | ENSG00000141744.2 | Other_Metabolism | N | N | N | N |
| 255 | PON1 | ENSG00000005421.4 | Other_Metabolism | N | N | N | N |
| 256 | PON2 | ENSG00000105854.7 | Other_Metabolism | N | N | N | N |
| 257 | PON3 | ENSG00000105852.6 | Other_Metabolism | N | N | N | N |
| 258 | POR | ENSG00000127948.9 | Other_Metabolism | N | N | N | N |
| 259 | PPARA | ENSG00000186951.11 | Nuclear Receptor/Transcripti on Factor | Y | N | N | N |
| 260 | PPARD | ENSG00000112033.9 | Nuclear Receptor/Transcripti on Factor | Y | N | N | N |
| 261 | PPARG | ENSG00000132170.15 | Nuclear Receptor/Transcripti on Factor | Y | N | N | N |
| 262 | PPARGC1A | ENSG00000109819.4 | Nuclear Receptor/Transcripti on Factor | N | N | N | N |
| 263 | PPP1R9A | ENSG00000158528.7 | Other | N | N | N | N |
| 264 | PRSS53 | ENSG00000151006.7 | Other | N | N | N | N |
| 265 | PSMB8 | ENSG00000204264.4 | Other | N | N | N | N |
| 266 | PTGIS | ENSG00000124212.3 | Other_Metabolism | Y | N | Y | N |
| 267 | PTGS1 | ENSG00000095303.10 | Other_Metabolism | Y | N | Y | N |
| 268 | PTGS2 | ENSG00000073756.7 | Other_Metabolism | Y | N | Y | N |
| 269 | QPRT | ENSG00000103485.12 | Other_Metabolism | Y | N | Y | N |
| 270 | RALBP1 | ENSG00000017797.6 | Other_Transporter | N | N | N | N |
| 271 | RPL13 | ENSG00000167526.9 | Other | N | N | N | N |
| 272 | RXRA | ENSG00000186350.8 | Nuclear Receptor/Transcripti on Factor | Y | N | N | N |

| | | | | | | | |
|-----|------------|--------------------|-----------------|---|---|---|---|
| 273 | RYR1 | ENSG00000196218.5 | Channel | Y | N | N | Y |
| 274 | RYR2 | ENSG00000198626.9 | Channel | N | N | N | N |
| 275 | SCN1B | ENSG00000105711.5 | Channel | Y | N | N | Y |
| 276 | SCN2B | ENSG00000149575.5 | Channel | Y | N | N | Y |
| 277 | SCN3B | ENSG00000166257.4 | Channel | Y | N | N | Y |
| 278 | SCN4B | ENSG00000177098.4 | Channel | Y | N | N | Y |
| 279 | SCN5A | ENSG00000183873.10 | Channel | Y | N | N | Y |
| 280 | SERPINA1 | ENSG00000197249.8 | Other | N | N | N | N |
| 281 | SERPINA7 | ENSG00000123561.10 | Other | N | N | N | N |
| 282 | SLC10A1 | ENSG00000100652.4 | SLC_Transporter | N | N | N | N |
| 283 | SLC10A2 | ENSG00000125255.5 | SLC_Transporter | N | N | N | N |
| 284 | SLC13A1 | ENSG00000081800.4 | SLC_Transporter | N | N | N | N |
| 285 | SLC13A2 | ENSG00000007216.9 | SLC_Transporter | N | N | N | N |
| 286 | SLC13A3 | ENSG00000158296.9 | SLC_Transporter | N | N | N | N |
| 287 | SLC15A1 | ENSG00000088386.9 | SLC_Transporter | N | N | N | N |
| 288 | SLC15A2 | ENSG00000163406.5 | SLC_Transporter | N | N | N | N |
| 289 | SLC16A1 | ENSG00000155380.7 | SLC_Transporter | N | N | N | N |
| 290 | SLC19A1 | ENSG00000173638.13 | SLC_Transporter | N | N | N | N |
| 291 | SLC22A1 | ENSG00000175003.8 | SLC_Transporter | N | N | N | N |
| 292 | SLC22A10 | ENSG00000184999.7 | SLC_Transporter | N | N | N | N |
| 293 | SLC22A11 | ENSG00000168065.11 | SLC_Transporter | Y | N | N | N |
| 294 | SLC22A12 | ENSG00000197891.7 | SLC_Transporter | Y | N | N | N |
| 295 | SLC22A13 | ENSG00000172940.7 | SLC_Transporter | N | N | N | N |
| 296 | SLC22A14 | ENSG00000144671.5 | SLC_Transporter | N | N | N | N |
| 297 | SLC22A15 | ENSG00000163393.8 | SLC_Transporter | N | N | N | N |
| 298 | SLC22A16 | ENSG00000004809.9 | SLC_Transporter | N | N | N | N |
| 299 | SLC22A17 | ENSG00000092096.10 | SLC_Transporter | N | N | N | N |
| 300 | SLC22A18 | ENSG00000110628.9 | SLC_Transporter | N | N | N | N |
| 301 | SLC22A18AS | ENSG00000254827.1 | SLC_Transporter | N | N | N | N |
| 302 | SLC22A2 | ENSG00000112499.7 | SLC_Transporter | N | N | N | N |
| 303 | SLC22A3 | ENSG00000146477.4 | SLC_Transporter | N | N | N | N |
| 304 | SLC22A4 | ENSG00000197208.5 | SLC_Transporter | Y | N | N | N |
| 305 | SLC22A5 | ENSG00000197375.7 | SLC_Transporter | Y | N | N | N |
| 306 | SLC22A6 | ENSG00000197901.6 | SLC_Transporter | N | N | N | N |
| 307 | SLC22A7 | ENSG00000137204.10 | SLC_Transporter | N | N | N | N |
| 308 | SLC22A8 | ENSG00000149452.10 | SLC_Transporter | Y | N | N | N |
| 309 | SLC22A9 | ENSG00000149742.5 | SLC_Transporter | N | N | N | N |
| 310 | SLC25A27 | ENSG00000153291.8 | SLC_Transporter | N | N | N | N |
| 311 | SLC27A1 | ENSG00000130304.10 | SLC_Transporter | N | N | N | N |
| 312 | SLC28A1 | ENSG00000156222.7 | SLC_Transporter | N | N | N | N |
| 313 | SLC28A2 | ENSG00000137860.7 | SLC_Transporter | N | N | N | N |
| 314 | SLC28A3 | ENSG00000197506.6 | SLC_Transporter | N | N | N | N |
| 315 | SLC29A1 | ENSG00000112759.11 | SLC_Transporter | N | N | N | N |

| | | | | | | | |
|-----|---------|--------------------|-------------------|---|---|---|---|
| 316 | SLC29A2 | ENSG00000174669.7 | SLC_Transporter | N | N | N | N |
| 317 | SLC2A4 | ENSG00000181856.10 | SLC_Transporter | Y | N | N | N |
| 318 | SLC2A5 | ENSG00000142583.11 | SLC_Transporter | Y | N | N | N |
| 319 | SLC47A1 | ENSG00000142494.7 | SLC_Transporter | N | N | N | N |
| 320 | SLC5A6 | ENSG00000138074.9 | SLC_Transporter | N | N | N | N |
| 321 | SLC6A3 | ENSG00000142319.14 | SLC_Transporter | Y | N | N | N |
| 322 | SLC6A4 | ENSG00000108576.4 | SLC_Transporter | Y | N | N | N |
| 323 | SLC6A6 | ENSG00000131389.12 | SLC_Transporter | N | N | N | N |
| 324 | SLC7A5 | ENSG00000103257.4 | SLC_Transporter | N | N | N | N |
| 325 | SLC7A7 | ENSG00000155465.13 | SLC_Transporter | N | N | N | N |
| 326 | SLC7A8 | ENSG00000092068.13 | SLC_Transporter | N | N | N | N |
| 327 | SLCO1A2 | ENSG00000084453.12 | SLC_Transporter | N | N | N | N |
| 328 | SLCO1B1 | ENSG00000134538.2 | SLC_Transporter | N | N | N | N |
| 329 | SLCO1B3 | ENSG00000111700.8 | SLC_Transporter | N | N | N | N |
| 330 | SLCO1C1 | ENSG00000139155.4 | SLC_Transporter | N | N | N | N |
| 331 | SLCO2A1 | ENSG00000174640.8 | SLC_Transporter | N | N | N | N |
| 332 | SLCO2B1 | ENSG00000137491.9 | SLC_Transporter | N | N | N | N |
| 333 | SLCO3A1 | ENSG00000176463.8 | SLC_Transporter | N | N | N | N |
| 334 | SLCO4A1 | ENSG00000101187.10 | SLC_Transporter | N | N | N | N |
| 335 | SLCO4C1 | ENSG00000173930.8 | SLC_Transporter | N | N | N | N |
| 336 | SLCO5A1 | ENSG00000137571.5 | SLC_Transporter | N | N | N | N |
| 337 | SLCO6A1 | ENSG00000205359.5 | SLC_Transporter | N | N | N | N |
| 338 | SOD2 | ENSG00000112096.11 | Other_Metabolism | N | N | N | N |
| 339 | SPG7 | ENSG00000197912.8 | Other | N | N | N | N |
| 340 | SPN | ENSG00000197471.6 | Other | N | N | N | N |
| 341 | SPP1 | ENSG00000118785.8 | Other | N | N | N | N |
| 342 | SULT1A1 | ENSG00000196502.7 | SULT_Metabolism | N | N | N | N |
| 343 | SULT1A2 | ENSG00000197165.6 | SULT_Metabolism | N | N | N | N |
| 344 | SULT1A3 | ENSG00000261052.1 | SULT_Metabolism | N | N | N | N |
| 345 | SULT1B1 | ENSG00000173597.3 | SULT_Metabolism | N | N | N | N |
| 346 | SULT1C2 | ENSG00000198203.5 | SULT_Metabolism | N | N | N | N |
| 347 | SULT1C4 | ENSG00000198075.5 | SULT_Metabolism | N | N | N | N |
| 348 | SULT1E1 | ENSG00000109193.6 | SULT_Metabolism | N | N | N | N |
| 349 | SULT2A1 | ENSG00000105398.3 | SULT_Metabolism | N | N | N | N |
| 350 | SULT2B1 | ENSG00000088002.6 | SULT_Metabolism | N | N | N | N |
| 351 | SULT4A1 | ENSG00000130540.9 | SULT_Metabolism | N | N | N | N |
| 352 | TAP1 | ENSG00000168394.9 | Other_Transporter | N | N | N | N |
| 353 | TBXAS1 | ENSG00000059377.10 | Other_Metabolism | Y | N | Y | N |
| 354 | TCL1A | ENSG00000100721.6 | Other | N | N | N | N |
| 355 | TGFB1 | ENSG00000105329.4 | Other | N | N | N | N |
| 356 | TGFB2 | ENSG00000092969.7 | Other | Y | N | N | N |
| 357 | TGFB3 | ENSG00000119699.3 | Other | N | N | N | N |
| 358 | TGFBI | ENSG00000120708.9 | Other | N | N | N | N |

| | | | | | | | |
|-----|----------|--------------------|--|---|---|---|---|
| 359 | TNF | ENSG00000232810.3 | Other | Y | N | N | N |
| 360 | TNFRSF1A | ENSG00000067182.3 | Other | Y | N | N | N |
| 361 | TNFRSF1B | ENSG00000028137.11 | Other | Y | N | N | N |
| 362 | TPH1 | ENSG00000129167.5 | Other_Metabolism | Y | N | Y | N |
| 363 | TPH2 | ENSG00000139287.7 | Other_Metabolism | N | N | N | N |
| 364 | TPMT | ENSG00000137364.4 | Other_Metabolism | N | N | N | N |
| 365 | TPSG1 | ENSG00000116176.6 | Other | N | N | N | N |
| 366 | TYMS | ENSG00000176890.10 | Other_Metabolism | Y | N | Y | N |
| 367 | UGT1A1 | ENSG00000241635.2 | UGT_Metabolism | N | N | N | N |
| 368 | UGT1A10 | ENSG00000242515.1 | UGT_Metabolism | N | N | N | N |
| 369 | UGT1A3 | ENSG00000243135.1 | UGT_Metabolism | N | N | N | N |
| 370 | UGT1A4 | ENSG00000244474.1 | UGT_Metabolism | N | N | N | N |
| 371 | UGT1A5 | ENSG00000240224.1 | UGT_Metabolism | N | N | N | N |
| 372 | UGT1A6 | ENSG00000167165.11 | UGT_Metabolism | N | N | N | N |
| 373 | UGT1A7 | ENSG00000244122.2 | UGT_Metabolism | N | N | N | N |
| 374 | UGT1A8 | ENSG00000242366.1 | UGT_Metabolism | N | N | N | N |
| 375 | UGT1A9 | ENSG00000241119.1 | UGT_Metabolism | N | N | N | N |
| 376 | UGT2A1 | ENSG00000173610.6 | UGT_Metabolism | N | N | N | N |
| 377 | UGT2B10 | ENSG00000109181.7 | UGT_Metabolism | N | N | N | N |
| 378 | UGT2B11 | ENSG00000213759.4 | UGT_Metabolism | N | N | N | N |
| 379 | UGT2B15 | ENSG00000196620.4 | UGT_Metabolism | N | N | N | N |
| 380 | UGT2B17 | ENSG00000197888.2 | UGT_Metabolism | N | N | N | N |
| 381 | UGT2B28 | ENSG00000135226.12 | UGT_Metabolism | N | N | N | N |
| 382 | UGT2B4 | ENSG00000156096.8 | UGT_Metabolism | N | N | N | N |
| 383 | UGT2B7 | ENSG00000171234.9 | UGT_Metabolism | N | N | N | N |
| 384 | UGT8 | ENSG00000174607.6 | UGT_Metabolism | N | N | N | N |
| 385 | VDR | ENSG00000111424.6 | Nuclear Receptor/Transcripti on Factor | Y | N | N | N |
| 386 | VKORC1 | ENSG00000167397.10 | Other | Y | N | N | N |
| 387 | XDH | ENSG00000158125.5 | Other_Metabolism | Y | N | Y | N |
| 388 | XRCC1 | ENSG00000073050.5 | Other Nuclear | N | N | N | N |
| 389 | ZNF423 | ENSG00000102935.7 | Receptor/Transcripti on Factor | N | N | N | N |

Supplemental Table S2. The population demographic information of the human (i) liver tissues, (ii) kidney tissues, (iii) heart atrial tissues, (iv) adipose tissue and (v) lymphoblastoid cell lines

(i) Human liver tissues

| Number | Tissue | Age | Sex | Race | Tissue Source | Selected 18 samples for subsampling analysis | Number of Raw Reads | Number of Unique Mapped Reads |
|--------|--------|-----|--------|-----------|---|--|---------------------|-------------------------------|
| 1 | Liver | 75 | Female | Caucasian | | Y | 74067026 | 34956769 |
| 2 | Liver | 72 | Male | Caucasian | | Y | 84596342 | 45728515 |
| 3 | Liver | 68 | Female | Caucasian | | N | 104114760 | 17720652 |
| 4 | Liver | 62 | Male | Caucasian | | Y | 68202500 | 35937587 |
| 5 | Liver | 53 | Male | Caucasian | | Y | 80599340 | 44339114 |
| 6 | Liver | 28 | Male | Caucasian | These samples were normal postmortem human liver that were obtained through the Liver Tissue Procurement and Distribution System (University of Pittsburgh, Pennsylvania). Ref: Schadt, EE et al. Mapping the genetic architecture of gene expression in human liver. PLoS Biol. 6(5), e107 (2008). | N | 59695274 | 15933223 |
| 7 | Liver | 45 | Male | Caucasian | | Y | 77870534 | 28870565 |
| 8 | Liver | 54 | Male | Caucasian | | Y | 94573624 | 45599306 |
| 9 | Liver | 60 | Male | Caucasian | | N | 63973708 | 14390113 |
| 10 | Liver | 60 | Male | Caucasian | | N | 70802816 | 21585499 |
| 11 | Liver | 67 | Male | Caucasian | | Y | 67874018 | 35489635 |
| 12 | Liver | 15 | Female | Caucasian | | Y | 73733946 | 38910060 |
| 13 | Liver | 66 | Female | Caucasian | | Y | 69714872 | 32125879 |
| 14 | Liver | 57 | Male | Caucasian | | Y | 71821034 | 35512918 |
| 15 | Liver | 49 | Male | Caucasian | | Y | 91979674 | 53216324 |
| 16 | Liver | 68 | Male | Caucasian | | Y | 71825386 | 43402609 |
| 17 | Liver | 16 | Female | Caucasian | | Y | 62880672 | 26062674 |
| 18 | Liver | 75 | Female | Caucasian | | N | 51671476 | 9583751 |
| 19 | Liver | 30 | Female | Caucasian | | N | 93870408 | 45110798 |
| 20 | Liver | 47 | Female | Caucasian | | Y | 87331202 | 52582049 |
| 21 | Liver | 53 | Male | Caucasian | | Y | 97121978 | 44788608 |
| 22 | Liver | 56 | Male | Caucasian | | Y | 91811956 | 42282929 |
| 23 | Liver | 47 | Female | Caucasian | | Y | 110671808 | 51553038 |
| 24 | Liver | 70 | Male | Caucasian | | Y | 84448060 | 44540884 |

(ii) Human kidney tissues

| Number | Tissue | Age | Sex | Race | Tissue Source | Selected 18 samples for subsampling analysis | Number of Raw Reads | Number of Unique Mapped Reads |
|--------|---------------|-----|--------|-----------|---------------|--|---------------------|-------------------------------|
| 1 | Kidney Cortex | 56 | Female | Caucasian | | Y | 62779252 | 45253435 |
| 3 | Kidney Cortex | 46 | Female | Caucasian | | Y | 58792770 | 46005702 |
| 5 | Kidney Cortex | 69 | Female | Caucasian | | N | 59355760 | 22159488 |
| 6 | Kidney Cortex | 55 | Male | Caucasian | | Y | 55527738 | 38728138 |
| 7 | Kidney Cortex | 55 | Male | Caucasian | | Y | 53197840 | 26905312 |
| 9 | Kidney Cortex | 52 | Male | Caucasian | | Y | 64374362 | 26904786 |

| | | | | | | | | |
|----|---------------|----|--------|-----------|--|---|----------|----------|
| 10 | Kidney Cortex | 90 | Female | Caucasian | | Y | 93557570 | 52642042 |
| 11 | Kidney Cortex | 38 | Female | Caucasian | The samples were normal | Y | 89809126 | 64068201 |
| 13 | Kidney Cortex | 4 | Female | Caucasian | postmortom or biospy kidney | Y | 52480948 | 43258580 |
| 17 | Kidney Cortex | 53 | Male | Caucasian | samples (renal cortex) purchased from Asterand (Detroit, USA) or Captial Biosciences (Rockville, USA). Ref: Dahlin, A et al. Gene expression profiling of transporters in the solute carrere and ATP-binding cassette superfamilies in human eye substructures. Mol Pharm. 10(2), 650-63 (2013). | Y | 73674810 | 40695337 |
| 18 | Kidney Cortex | 8 | Male | Caucasian | | Y | 60115224 | 27734510 |
| 19 | Kidney Cortex | 45 | Male | Caucasian | | Y | 60233332 | 40856985 |
| 21 | Kidney Cortex | 4 | Female | Caucasian | | Y | 52559678 | 35445455 |
| 24 | Kidney Cortex | 43 | Male | Caucasian | | Y | 64779326 | 38887558 |
| 25 | Kidney Cortex | 6 | Female | Caucasian | | Y | 61298068 | 31392534 |
| 28 | Kidney Cortex | 52 | Female | Caucasian | | Y | 72942822 | 37827074 |
| 29 | Kidney Cortex | 46 | Male | Caucasian | | Y | 54346380 | 35303709 |
| 30 | Kidney Cortex | 62 | Male | Caucasian | | Y | 48339104 | 29641115 |
| 31 | Kidney Cortex | 79 | Female | Caucasian | | Y | 71638562 | 34751600 |
| 32 | Kidney Cortex | 68 | Male | Caucasian | | N | 45190234 | 19613545 |

(iii) Human heart ventricle tissues

| Number | Tissue | Age | Sex | Race | Tissue Source | Selected 18 samples for subsampling analysis | Number of Raw Reads | Number of Unique Mapped Reads |
|--------|-----------------|-----|-----|-----------|--|--|---------------------|-------------------------------|
| 1 | Heart ventricle | 34 | M | Caucasian | | Y | 89986426 | 57496576 |
| 2 | Heart ventricle | 27 | F | Caucasian | National Disease Research Interchange (NDRI, Philadelphia, PA, USA) or National Institute of Child Health & Human Development Brain and Tissue Bank (NICHD, Baltimore, MD, USA). All Specimens were collected from | Y | 84793502 | 55413159 |
| 3 | Heart ventricle | 15 | F | Caucasian | | N | 70404508 | 41813523 |
| 4 | Heart ventricle | 42 | F | Caucasian | | Y | 71134668 | 35079948 |
| 5 | Heart ventricle | 54 | F | Caucasian | | Y | 86216410 | 54037908 |
| 6 | Heart ventricle | 18 | M | Caucasian | | N | 171225890 | 97410738 |
| 7 | Heart ventricle | 60 | M | Caucasian | | Y | 84675428 | 55369577 |
| 8 | Heart ventricle | 56 | M | Caucasian | | N | 83193276 | 49752663 |
| 9 | Heart ventricle | 41 | M | Caucasian | | Y | 73803614 | 45942077 |
| 10 | Heart ventricle | 57 | F | Caucasian | | Y | 96611370 | 58603837 |
| 11 | Heart ventricle | 20 | M | Caucasian | | Y | 67776840 | 40658757 |
| 12 | Heart ventricle | 39 | F | Caucasian | | Y | 89552672 | 48026027 |
| 13 | Heart ventricle | 50 | M | Caucasian | | Y | 67834636 | 40110806 |
| 14 | Heart ventricle | 48 | F | Caucasian | | Y | 80153734 | 44163960 |
| 15 | Heart ventricle | 52 | M | Caucasian | | Y | 152250688 | 78898295 |

| | | | | | | | | |
|----|-----------------|----|---|-----------|--|---|----------|----------|
| 16 | Heart ventricle | 38 | M | Caucasian | | Y | 69862644 | 35314685 |
| 17 | Heart ventricle | 21 | M | Caucasian | | Y | 70506838 | 42647395 |
| 18 | Heart ventricle | 40 | F | Caucasian | | N | 83527236 | 54878424 |
| 19 | Heart ventricle | 63 | F | Caucasian | | N | 77684194 | 49045169 |
| 20 | Heart ventricle | 54 | M | Caucasian | | Y | 81806578 | 49297686 |
| 21 | Heart ventricle | 58 | M | Caucasian | | Y | 82028022 | 52460405 |
| 22 | Heart ventricle | 41 | M | Caucasian | | Y | 86796980 | 56908512 |
| 23 | Heart ventricle | 32 | F | Caucasian | | Y | 75019736 | 50086176 |
| 24 | Heart ventricle | 25 | F | Caucasian | | N | 71450592 | 49037737 |
| 25 | Heart ventricle | 19 | M | Caucasian | | N | 74759838 | 49510692 |

(iv) Human adipose tissues

| Number | Tissue | Age | Sex | Race | Tissue Source | Selected 18 samples for subsampling analysis | Number of Raw Reads | Number of Unique Mapped Reads |
|--------|---------|-----|--------|------------------|---|--|---------------------|-------------------------------|
| 1 | Adipose | 55 | Female | White | | Y | 85736534 | 59519669 |
| 2 | Adipose | 36 | Female | White | These adipose tissue biopsy specimens were collected from | Y | 83640366 | 59602281 |
| 3 | Adipose | 47 | Male | African American | human | N | 49447548 | 34783714 |
| 4 | Adipose | 31 | Female | African American | participants in a dietary intervention | N | 73916270 | 54369960 |
| 5 | Adipose | 34 | Female | Asian | clinical trial during the control diet (55% carbohydrate, 30% fat). | N | 88304362 | 63241541 |
| 6 | Adipose | 56 | Female | White | Participants were ≥ 18 years old, non-smoking, and overweight to obese with BMI between 25 and 40 kg/m2 but otherwise healthy. Ref: Chiu, S et al. Diets high in protein or saturated fat do not affect insulin sensitivity or plasma concentrations of lipids and lipoproteins in overweight and obese adults. J Nutr. 144(11), 1753-9 (2014). | Y | 93083806 | 64193681 |
| 7 | Adipose | 56 | Female | White | | Y | 82543362 | 55664950 |
| 8 | Adipose | 23 | Female | African American | | N | 53586144 | 39623296 |
| 9 | Adipose | 42 | Female | unknown | | Y | 61709462 | 45082859 |
| 10 | Adipose | 23 | Female | unknown | | Y | 67271848 | 46964491 |
| 11 | Adipose | 57 | Female | White | | Y | 66104928 | 43979935 |
| 12 | Adipose | 25 | Female | White | | Y | 49547238 | 34909751 |
| 13 | Adipose | 45 | Female | White | | Y | 50875584 | 37640312 |
| 14 | Adipose | 41 | Female | White | | Y | 60135280 | 40939107 |
| 15 | Adipose | 41 | Male | White | | Y | 65089562 | 46673558 |
| 16 | Adipose | 35 | Male | African American | | N | 67916144 | 46874501 |
| 17 | Adipose | 24 | Female | Asian | | N | 50115470 | 36854289 |
| 18 | Adipose | 28 | Female | White | | Y | 61975066 | 44723046 |
| 19 | Adipose | 52 | Male | White | | Y | 80692410 | 56394164 |
| 20 | Adipose | 59 | Female | unknown | | Y | 70007138 | 46842617 |
| 21 | Adipose | 52 | Female | unknown | | Y | 62487308 | 42074173 |
| 22 | Adipose | 29 | Female | White | | Y | 102082378 | 67896823 |
| 23 | Adipose | 43 | Male | White | | Y | 58759486 | 46246447 |
| 24 | Adipose | 30 | Female | unknown | | Y | 55097874 | 42835016 |
| 25 | Adipose | 36 | Female | Asian | | N | 54637216 | 42445588 |

(v) Lymphoblastoid cell lines

| Number | Tissue | Age | Sex | Race | Source | Selected 18 samples for subsampling analysis | Number of Raw Reads | Number of Unique Mapped Reads |
|--------|-------------------------------------|-------|--------|-----------|---|--|---------------------|-------------------------------|
| 1 | Cells - EBV transformed lymphocytes | 32.78 | Male | Caucasian | | Y | 69972926 | 46443636 |
| 2 | Cells - EBV transformed lymphocytes | 39.79 | Male | Caucasian | Immortalized lymphoblastoid cell lines (LCLs) were derived from blood samples isolated from participants of the Cholesterol and | Y | 75594480 | 53463208 |
| 3 | Cells - EBV transformed lymphocytes | 36.61 | Female | Caucasian | Pharmacogenetics (CAP) clinical trial, and grown at 37°C with 5% CO2 in RPMI | N | 74795574 | 52297675 |
| 4 | Cells - EBV transformed lymphocytes | 60.16 | Female | Caucasian | 1640 media supplemented with 10% FBS, 500 U/ml penicillin/streptomycin, and 2 | N | 85471302 | 48592209 |
| 5 | Cells - EBV transformed lymphocytes | 49.17 | Male | Caucasian | nmol/L GlutaMAX (Life Technologies). Ref: Simon, JA. Phenotypic predictors of response to simvastatin therapy among African- | Y | 92783426 | 64415559 |
| 6 | Cells - EBV transformed lymphocytes | 75.38 | Female | Caucasian | Americans and Caucasians: the Cholesterol and Pharmacogenetics (CAP) Study. 97(6), 843-50 (2006). | N | 58268928 | 43472851 |
| 7 | Cells - EBV transformed lymphocytes | 68.27 | Male | Caucasian | | N | 55648310 | 36045052 |
| 8 | Cells - EBV transformed lymphocytes | 55.52 | Female | Caucasian | | Y | 68522488 | 51089785 |
| 9 | Cells - EBV transformed lymphocytes | 48.39 | Female | Caucasian | | N | 58630148 | 38834141 |

| | | | | | | | |
|----|--|-------|--------|-----------|---|-----------|----------|
| 10 | Cells - EBV transformed lymphocytes | 48.11 | Male | Caucasian | Y | 84444016 | 56091455 |
| 11 | Cells - EBV transformed lymphocytes | 54.97 | Male | Caucasian | N | 61357514 | 43939195 |
| 12 | Cells - EBV transformed lymphocytes | 30.14 | Male | Caucasian | Y | 101160604 | 71356057 |
| 13 | Cells - EBV transformed lymphocytes | 57.2 | Female | Caucasian | Y | 115794752 | 74586887 |
| 14 | Cells - EBV transformed lymphocytes | 58.95 | Female | Caucasian | N | 72885284 | 47346008 |
| 15 | Cells - EBV transformed lymphocytes | 35.15 | Male | Caucasian | Y | 152314160 | 96570426 |
| 16 | Cells - EBV transformed lymphocytes | 47.5 | Female | Caucasian | N | 82053168 | 53286669 |
| 17 | Cells - EBV transformed lymphocytes | 43.72 | Male | Caucasian | N | 109555426 | 72306303 |
| 18 | Cells - EBV transformed lymphocytes | 47.9 | Male | Caucasian | N | 85930840 | 56313704 |
| 19 | Cells - EBV transformed lymphocytes | 61.61 | Male | Caucasian | N | 51594666 | 39295502 |

| | | | | | | | |
|----|--|-------|--------|-----------|---|-----------|----------|
| 20 | Cells - EBV transformed lymphocytes | 39.38 | Female | Caucasian | Y | 76508342 | 49645812 |
| 21 | Cells - EBV transformed lymphocytes | 55.3 | Male | Caucasian | Y | 60053104 | 44091975 |
| 22 | Cells - EBV transformed lymphocytes | 34.79 | Female | Caucasian | N | 66652646 | 45631941 |
| 23 | Cells - EBV transformed lymphocytes | 55.34 | Male | Caucasian | Y | 74609996 | 53514458 |
| 24 | Cells - EBV transformed lymphocytes | 56.59 | Female | Caucasian | N | 102911154 | 75177432 |
| 25 | Cells - EBV transformed lymphocytes | 55.14 | Male | Caucasian | N | 65205334 | 49505425 |
| 26 | Cells - EBV transformed lymphocytes | 54.86 | Female | Caucasian | N | 55295558 | 40638125 |
| 27 | Cells - EBV transformed lymphocytes | 66.82 | Female | Caucasian | Y | 129585604 | 72749855 |
| 28 | Cells - EBV transformed lymphocytes | 62.46 | Female | Caucasian | Y | 122101926 | 74173449 |
| 29 | Cells - EBV transformed lymphocytes | 53.09 | Female | Caucasian | N | 87917948 | 61659547 |

| | | | | | | | |
|----|--|-------|--------|-----------|---|-----------|----------|
| 30 | Cells - EBV transformed lymphocytes | 61.57 | Male | Caucasian | Y | 109350692 | 73321404 |
| 31 | Cells - EBV transformed lymphocytes | 53.37 | Female | Caucasian | N | | 65485414 |
| 32 | Cells - EBV transformed lymphocytes | 59.04 | Male | Caucasian | N | | 53225501 |
| 33 | Cells - EBV transformed lymphocytes | 37.86 | Male | Caucasian | Y | 64469612 | 43366971 |
| 34 | Cells - EBV transformed lymphocytes | 42.07 | Male | Caucasian | Y | 62572380 | 45370734 |
| 35 | Cells - EBV transformed lymphocytes | 50.87 | Male | Caucasian | N | 69861558 | 48770638 |
| 36 | Cells - EBV transformed lymphocytes | 53.45 | Female | Caucasian | N | 60815498 | 45235275 |
| 37 | Cells - EBV transformed lymphocytes | 68.18 | Male | Caucasian | N | | 56501103 |
| 38 | Cells - EBV transformed lymphocytes | 66.82 | Female | Caucasian | N | 72643362 | 51300794 |
| 39 | Cells - EBV transformed lymphocytes | 52.41 | Male | Caucasian | N | 89283478 | 60251207 |

| | | | | | | | |
|----|--|-------|--------|-----------|---|----------|----------|
| 40 | Cells - EBV transformed lymphocytes | 39.83 | Female | Caucasian | N | 90255134 | 56119858 |
| 41 | Cells - EBV transformed lymphocytes | 60.42 | Male | Caucasian | N | 66256126 | 47099855 |
| 42 | Cells - EBV transformed lymphocytes | 62.29 | Female | Caucasian | N | 72326344 | 48102041 |
| 43 | Cells - EBV transformed lymphocytes | 54.01 | Male | Caucasian | Y | 78219746 | 56276095 |
| 44 | Cells - EBV transformed lymphocytes | 35.22 | Male | Caucasian | Y | 86976208 | 60067824 |
| 45 | Cells - EBV transformed lymphocytes | 44.24 | Male | Caucasian | N | 84188582 | 54902701 |

Supplemental Table S3. Summary of gene expression for the tissues

| (a) PHARMACOGENES | LCL | Liver | Kidney | Adipose | Heart | Intersection | Union |
|--|------------|--------------|---------------|----------------|--------------|---------------------|--------------|
| Total Number of Genes Mapped and Analyzed | 389 | 387* | 389 | 389 | 389 | 389 | 389 |
| Ubiquitous¹ | 116 | 225 | 167 | 190 | 166 | 87 | 291 |
| Total Expressed² | 188 | 320 | 315 | 274 | 255 | 161 | 364 |
| Total Undetected³ | 17 | 3 | 5 | 1 | 5 | 0 | 22 |
| Number of Specific Genes³ | 3 | 39 | 14 | 3 | 9 | NA | NA |
| % Ubiquitous (Ubiquitous/Total) | 29.80% | 58.10% | 42.90% | 48.80% | 42.70% | 22.40% | 74.81% |
| % Ubiquitous (Ubiquitous/Total Expressed) | 61.70% | 70.30% | 53.00% | 69.30% | 65.10% | 54.00% | 79.95% |
| % Specific (Specific/Total Expressed) | 2.10% | 14.00% | 5.30% | 1.30% | 4.00% | NA | NA |
| | | | | | | | |
| (b) ALL PROTEIN CODING | LCL | Liver | Kidney | Adipose | Heart | Intersection | Union |
| Total Number of Genes Mapped and Analyzed | 20025 | 20012* | 20025 | 20025 | 20025 | 20025 | 20025 |
| Ubiquitous¹ | 9685 | 10375 | 10838 | 11274 | 10574 | 7845 | 13509 |
| Total Expressed² | 12772 | 14247 | 15416 | 14251 | 11223 | 11223 | 16888 |
| Total Undetected³ | 1643 | 1132 | 866 | 725 | 1242 | 388 | 2183 |
| Number of Specific Genes⁴ | 418 | 305 | 494 | 248 | 290 | NA | NA |
| % Ubiquitous (Ubiquitous/Total) | 48.40% | 51.80% | 54.10% | 56.30% | 52.80% | 39.20% | 67.46% |
| % Ubiquitous (Ubiquitous/Total Expressed) | 75.80% | 72.80% | 70.30% | 79.10% | 94.20% | 69.90% | 79.99% |
| % Specific (Specific/Total Expressed) | 3.20% | 2.10% | 3.10% | 1.70% | 2.00% | NA | NA |

* Fewer number of genes mapped and analyzed in liver samples. For example in the liver, two pharmacogenes, ALB (albumin) and SERPINA1 (serpin peptidase inhibitor, clade A) were not able to be accurately quantified due to their high expression, and so these genes were excluded from liver analysis.

¹ Genes that have FPKM values ≥ 1 in all 18 individuals of each tissues or LCL.

² Total Expressed genes refers to genes that have FPKM ≥ 1 in any 18 individuals of each tissues or LCL.

³ Total undetected genes refers to genes that have FPKM = 0 in all 18 individuals of each tissues or LCL.

⁴ Number of specific genes refers to genes that have FPKM values ≥ 1 in one tissue only and other tissues have FPKM values < 1 . List of these genes in Supplementary Table 5.

Supplemental Table S4: Top 10 most variable gene sets (Top 20 for LCLs) (among protein coding genes with median FPKM >1) by tissue type. Enrichment of variability in gene expression in gene sets was calculated using the Gene Set Enrichment Analysis tool (GSEA, Subramanian A. et al. *PNAS* 2005;102(43):15545h 15550.), with coefficient of variation of each gene in a particular tissue type used as gene ranking. Gene sets tested include all gene ontology biological process sets with 15 to 500 genes, and 'PGRN pharmacogenes'. Significance of enrichment was calculated by permuting gene rank associations 1000 times. Raw enrichment scores, normalized enrichment scores (normalized by mean of enrichment scores over permutations), nominal p value from permutation, and false discovery rate q value over all gene sets shown below.

| Heart | | | | |
|---|-------------------------|------------------------------------|-----------------------|------------------------------------|
| Set Name | Enrichment Score | Normalized Enrichment Score | Nominal Pvalue | False Discovery Rate Qvalue |
| CELL_SURFACE_RECEPTOR_LINKED_SIGNAL_TRANSDUCTION_GO_0007166 | 0.24 | 5.24 | 0 | 0 |
| RESPONSE_TO_EXTERNAL_STIMULUS | 0.33 | 5.12 | 0 | 0 |
| G_PROTEIN_COUPLED_RECEPTOR_PROTEIN_SIGNALING_PATHWAY | 0.36 | 5.04 | 0 | 0 |
| IMMUNE_SYSTEM_PROCESS | 0.29 | 4.93 | 0 | 0 |
| IMMUNE_RESPONSE | 0.36 | 4.92 | 0 | 0 |
| DEFENSE_RESPONSE | 0.36 | 4.88 | 0 | 0 |
| CELL_CELL_SIGNALING | 0.28 | 4.40 | 0 | 0 |
| PGRN PHARMACOGENES | 0.25 | 4.19 | 0 | 0 |
| RESPONSE_TO_WOUNDING | 0.34 | 4.17 | 0 | 0 |
| LOCOMOTORY_BEHAVIOR | 0.52 | 4.04 | 0 | 0 |
| Kidney | | | | |
| PGRN PHARMACOGENES | 0.35 | 6.49 | 0 | 0 |
| DEFENSE_RESPONSE | 0.43 | 5.87 | 0 | 0 |
| RESPONSE_TO_EXTERNAL_STIMULUS | 0.35 | 5.44 | 0 | 0 |
| RESPONSE_TO_WOUNDING | 0.42 | 5.24 | 0 | 0 |
| IMMUNE_RESPONSE | 0.37 | 4.99 | 0 | 0 |
| IMMUNE_SYSTEM_PROCESS | 0.30 | 4.95 | 0 | 0 |
| INFLAMMATORY_RESPONSE | 0.45 | 4.72 | 0 | 0 |
| CELL_SURFACE_RECEPTOR_LINKED_SIGNAL_TRANSDUCTION_GO_0007166 | 0.21 | 4.60 | 0 | 0 |
| G_PROTEIN_COUPLED_RECEPTOR_PROTEIN_SIGNALING_PATHWAY | 0.31 | 4.43 | 0 | 0 |
| SYSTEM_PROCESS | 0.22 | 4.21 | 0 | 0 |
| Adipose Tissue | | | | |
| IMMUNE_SYSTEM_PROCESS | 0.30 | 5.54 | 0 | 0 |
| IMMUNE_RESPONSE | 0.35 | 5.37 | 0 | 0 |

| | | | | |
|---|-------------|-------------|----------|-----------------|
| DEFENSE_RESPONSE | 0.37 | 5.14 | 0 | 0 |
| BEHAVIOR | 0.45 | 4.84 | 0 | 0 |
| G_PROTEIN_COUPLED_RECEPTOR_PROTEIN_SIGNALING_PATHWAY | 0.32 | 4.50 | 0 | 0 |
| RESPONSE_TO_EXTERNAL_STIMULUS | 0.28 | 4.44 | 0 | 0 |
| LOCOMOTORY_BEHAVIOR | 0.49 | 4.38 | 0 | 0 |
| PGRN PHARMACOGENES | 0.25 | 4.14 | 0 | 0 |
| CELL_SURFACE_RECEPTOR_LINKED_SIGNAL_TRANSDUCTION_GO_0007166 | 0.19 | 4.13 | 0 | 0 |
| CELLULAR_DEFENSE_RESPONSE | 0.61 | 4.01 | 0 | 0 |
| Liver | | | | |
| PGRN PHARMACOGENES | 0.27 | 4.94 | 0 | 0 |
| CELL_CELL_SIGNALING | 0.28 | 4.14 | 0 | 0 |
| IMMUNE_RESPONSE | 0.27 | 3.91 | 0 | 0 |
| CELL_SURFACE_RECEPTOR_LINKED_SIGNAL_TRANSDUCTION_GO_0007166 | 0.18 | 3.82 | 0 | 0 |
| IMMUNE_SYSTEM_PROCESS | 0.22 | 3.77 | 0 | 0 |
| DEFENSE_RESPONSE | 0.23 | 3.35 | 0 | 0 |
| DIGESTION | 0.64 | 3.34 | 0 | 0 |
| G_PROTEIN_COUPLED_RECEPTOR_PROTEIN_SIGNALING_PATHWAY | 0.26 | 3.33 | 0 | 0 |
| SYSTEM_DEVELOPMENT | 0.13 | 3.23 | 0 | 0 |
| SYSTEM_PROCESS | 0.18 | 3.17 | 0 | 0 |
| LCLs | | | | |
| G_PROTEIN_COUPLED_RECEPTOR_PROTEIN_SIGNALING_PATHWAY | 0.45 | 5.11 | 0 | 0 |
| CELL_SURFACE_RECEPTOR_LINKED_SIGNAL_TRANSDUCTION_GO_0007166 | 0.28 | 5.06 | 0 | 0 |
| RESPONSE_TO_EXTERNAL_STIMULUS | 0.29 | 3.89 | 0 | 0 |
| CELL_CELL_SIGNALING | 0.31 | 3.87 | 0 | 0 |
| IMMUNE_RESPONSE | 0.25 | 3.52 | 0 | 0 |
| MULTICELLULAR_ORGANISMAL_DEVELOPMENT | 0.14 | 3.51 | 0 | 0 |
| BEHAVIOR | 0.40 | 3.48 | 0 | 0 |
| RESPONSE_TO_WOUNDING | 0.33 | 3.44 | 0 | 0 |
| SYSTEM_PROCESS | 0.22 | 3.30 | 0 | 0 |
| DEFENSE_RESPONSE | 0.26 | 3.29 | 0 | 0 |
| IMMUNE_SYSTEM_PROCESS | 0.20 | 3.23 | 0 | 0 |
| ANATOMICAL_STRUCTURE_DEVELOPMENT | 0.14 | 3.20 | 0 | 0 |
| LOCOMOTORY_BEHAVIOR | 0.42 | 3.09 | 0 | 0 |
| SYSTEM_DEVELOPMENT | 0.14 | 2.98 | 0 | 6.49E-05 |
| INFLAMMATORY_RESPONSE | 0.33 | 2.95 | 0 | 6.06E-05 |
| PGRN PHARMACOGENES | 0.22 | 2.92 | 0 | 1.17E-04 |

Supplemental Table S5A. List of PGRN pharmacogenes that are expressed at higher levels in a single tissue or LCLs in the dataset. These genes are expressed with FPKM at least 10 times greater than the FPKM in all the other tissues. Tissue-specific gene expression values were calculated by summing FPKM values for all isoforms for a given gene in a given tissue (FPKM values per tissue were calculated by Cuffdiff, one per tissue using 18 samples for that tissue).

| LCL | Liver | Kidney | Adipose | Heart |
|------------|--------------|---------------|----------------|--------------|
| CHST11 | ABCB11 | ABP1 | PPARG | CACNA1C |
| SPN | ABCB4 | CYP24A1 | | CACNB2 |
| TCL1A | ABCC2 | HSD11B2 | | KCNH2 |
| TNF | ABCG8 | SERPINA1 | | NPPB |
| TYMS | AC008537.2 | SLC13A1 | | RYR2 |
| | ADH1A | SLC13A2 | | SCN2B |
| | ADH1C | SLC22A11 | | SCN5A |
| | ADH4 | SLC22A12 | | |
| | AOX1 | SLC22A13 | | |
| | APOA1 | SLC22A2 | | |
| | APOA2 | SLC22A6 | | |
| | APOA4 | SLC22A8 | | |
| | APOB | SLC6A3 | | |
| | CHST13 | SPP1 | | |
| | CYP1A2 | SULT1C2 | | |
| | CYP21A2 | SULT2B1 | | |
| | CYP26A1 | UGT8 | | |
| | CYP2A13 | | | |
| | CYP2A6 | | | |
| | CYP2A7 | | | |
| | CYP2B6 | | | |
| | CYP2C18 | | | |
| | CYP2C19 | | | |
| | CYP2C8 | | | |
| | CYP2C9 | | | |
| | CYP2D6 | | | |
| | CYP2E1 | | | |
| | CYP3A4 | | | |
| | CYP3A43 | | | |
| | CYP3A5 | | | |
| | CYP3A7 | | | |
| | CYP4F11 | | | |
| | CYP4F3 | | | |

CYP7A1
CYP8B1
DBH
F2
F5
FOXA3
MAT1A
NAT2
NNMT
NR1I2
NR1I3
ORM1
ORM2
PON1
PON3
SERPINA7
SLC10A1
SLC22A1
SLC22A10
SLC22A9
SLCO1B1
SLCO1B3
SULT1B1
SULT1E1
SULT2A1
UGT1A1
UGT1A3
UGT1A4
UGT2B10
UGT2B15
UGT2B4
XDH

Supplemental Table S5B. List of PGRN pharmacogenes that are expressed at lower levels in only one tissue of the dataset. These genes are expressed with FPKM at least 10 times lower in one tissue relative to all other tissues or LCL analyzed in the dataset, and FPKM in other tissues greater than or equal to 1. Tissue-specific gene expression values were calculated by summing FPKM values for all isoforms for a given gene in a given tissue (FPKM values per tissue were calculated by Cuffdiff, one per tissue using 18 samples for that tissue).

| LCL | Liver | Kidney | Adipose | Heart |
|----------|-------|--------|---------|-------|
| EPHX1 | | | CYP2J2 | |
| COL1A1 | | | | |
| TGFB1 | | | | |
| APOE | | | | |
| EGFR | | | | |
| SULT1A1 | | | | |
| SLCO2A1 | | | | |
| CDA | | | | |
| SLC22A17 | | | | |
| GSTM5 | | | | |
| ATP7B | | | | |
| AOX1 | | | | |
| SPP1 | | | | |
| ADH1C | | | | |
| NR3C2 | | | | |
| SLC2A4 | | | | |
| SCN1B | | | | |
| ADRA1B | | | | |
| ABCA1 | | | | |
| CYP4F12 | | | | |
| PEAR1 | | | | |
| FCGR3A | | | | |
| SLC22A3 | | | | |
| SULT1C4 | | | | |
| SLC25A27 | | | | |
| ALDH1A1 | | | | |
| FMO3 | | | | |
| SLC7A8 | | | | |
| CYP39A1 | | | | |
| MAOA | | | | |
| ORM1 | | | | |
| ADH1B | | | | |
| AGTR1 | | | | |
| CES1 | | | | |
| PTGIS | | | | |
| MAOB | | | | |
| NNMT | | | | |

Supplemental Table S6. A total of 20 pairwise comparisons were performed to detect the genes differentially expressed between LCLs and tissues for all protein coding genes (red) and pharmacogenes (blue). The **bold** numbers are the gene expression (FPKM) Spearman correlations between two tissues for tested genes. The numbers inside the parentheses refer to the number of genes differentially expressed between pairs of tissues (U: higher in row tissue/D: higher in column tissue). Genes are considered to be differentially expressed when $q < 0.10$ in both DESeq and Cuffdiff and >2 fold difference in expression. Darker shading indicates higher correlation.

| Pharmacogenes | | | | | |
|----------------------|--------------------------------|--------------------------------|--------------------------------|--------------------------------|-----------------------------|
| | Liver | Kidney | Adipose | Heart | LCL |
| Liver | | 0.40 (U:119/D:69) | 0.43 (U:134/D:48) | 0.31 (U:141/D:58) | 0.27 (U:173/D:38) |
| Kidney | 0.87 (U:3540/D:3023) | | 0.64 (U:94/D:51) | 0.61 (U:94/D:48) | 0.51 (U:151/D:39) |
| Adipose | 0.85 (U:3707/D:3862) | 0.87 (U:2940/D:3576) | | 0.83 (U:59/D:46) | 0.62 (U:117/D:38) |
| Heart | 0.82 (U:3828/D:3802) | 0.85 (U:2966/D:3335) | 0.9 (U:3118/D:3275) | | 0.62 (U:115/D:39) |
| LCL | 0.76 (U:5113/D:3713) | 0.76 (U:5198/D:4265) | 0.77 (U:5848/D:3781) | 0.75 (U:5360/D:3907) | |

Protein-coding genes

Supplemental Table S7. Percent of PGRN pharmacogenes that are alternatively spliced by class. Alternatively spliced genes have multiple mutually exclusive junctions each with at least 1 read/100bp and PSI>5 in at least one of the 90 samples. Genes reported as not alternatively spliced were not reported to have any evidence of mutually exclusive junctions in any sample, and have gene FPKM>10 in at least one sample. For other genes, it's unclear because the PSI may be below 5 or the gene may be low expressed and so some alternative splice events may not be observed.

| class | #genes | alt. spliced genes | not alt. spliced genes | unclear | % alt. spliced | % not alt. spliced |
|----------------|------------|--------------------|------------------------|-----------|----------------|--------------------|
| Other_Transp | 4 | 4 | 0 | 0 | 100.0% | 0.0% |
| ADH_Metabo | 7 | 6 | 0 | 1 | 85.7% | 0.0% |
| Other_Metab | 54 | 45 | 5 | 4 | 83.3% | 9.3% |
| ABC_Transpor | 24 | 20 | 1 | 3 | 83.3% | 4.2% |
| UGT_Metabol | 18 | 15 | 1 | 2 | 83.3% | 5.6% |
| SULT_Metabc | 10 | 8 | 0 | 2 | 80.0% | 0.0% |
| SLC_Transpor | 56 | 43 | 5 | 8 | 76.8% | 8.9% |
| Other | 77 | 55 | 9 | 13 | 71.4% | 11.7% |
| ALDH_Metabol | 7 | 5 | 0 | 2 | 71.4% | 0.0% |
| GST_Metabol | 17 | 12 | 1 | 4 | 70.6% | 5.9% |
| Nuclear Recept | 24 | 16 | 7 | 1 | 66.7% | 29.2% |
| CYP_Metabol | 47 | 30 | 6 | 11 | 63.8% | 12.8% |
| Receptor | 29 | 13 | 5 | 11 | 44.8% | 17.2% |
| Channel | 15 | 6 | 5 | 4 | 40.0% | 33.3% |
| Total | 389 | 278 | 45 | 66 | 71.5% | 11.6% |

Supplemental Table S8. A total of 20 pairwise comparisons were performed to detect the genes differentially alternative spliced between LCLs and tissues for all protein coding genes (red) and pharmacogenes (blue). Reported are the number of genes (**bold**) with a significantly differentially spliced event (in parentheses is the percent of tested events that were significant). Significant splicing events were determined by a Wilcoxon test on the 'percent spliced in' (PSI) values between two tissues (Benjamini-Hochberg corrected p-value <0.05) and the difference in median PSI between the tissues had to be >5. To be tested, an event must have a coverage of at least 10 reads/100bp in at least half the samples for each of the two tissues. Darker shading indicates a smaller percentage of events are differentially spliced.

| Pharmacogenes | | | | | |
|----------------------|----------------------|----------------------|----------------------|----------------------|--------------------|
| | Liver | Kidney | Adipose | Heart | LCL |
| Liver | | 18 (6.3%) | 14 (8.2%) | 10 (8.8%) | 14 (15%) |
| Kidney | 590 (9.2%) | | 12 (10%) | 8 (6.1%) | 14 (16%) |
| Adipose | 849 (14%) | 826 (12%) | | 12 (13%) | 19 (23%) |
| Heart | 787 (15%) | 743 (12%) | 1021 (16%) | | 16 (21%) |
| LCL | 1246 (21%) | 1408 (19%) | 1538 (21%) | 1403 (21%) | |

Protein-coding genes

Supplemental Table S9: The number of alternative splicing events (A) or genes with alternative splicing events (B) with at least 1 read/100bp and PSI>5 in one tissue and no coverage in any of the other four tissues. The potentially alternatively spliced region must have read coverage of at least 20 reads/100bp in at least 5 samples of each of the other four tissues to control for gene expression differences between tissues.

A Number of splice events observed in only one tissue (# of events in regions with read coverage >20reads/10bbp in at least 5 samples of all four other tissues)

| Tissue | Protein-Coding Genes | Pharmacogenes |
|---------|----------------------|-----------------|
| Adipose | 20 (of 3718, 0.5%) | 2 (of 52, 3.8%) |
| Heart | 43 (of 3862, 1.1%) | 1 (of 54, 1.9%) |
| Liver | 20 (of 4061, 0.5%) | 1 (of 53, 1.9%) |
| Kidney | 24 (of 3582, 0.7%) | 1 (of 48, 2.1%) |
| LCLs | 63 (of 3874, 1.6%) | 2 (of 75, 2.7%) |

B Number of genes with a splice event observed in only one tissue (# of genes with an event in a region with read coverage >20reads/10bbp in at least 5 samples of all four other tissues)

| Tissue | Protein-Coding Genes | Pharmacogenes |
|---------|----------------------|-----------------|
| Adipose | 22 (of 2152, 1.0%) | 1 (of 21, 4.8%) |
| Heart | 51 (of 2264, 2.3%) | 0 (of 23, 0.0%) |
| Liver | 22 (of 2285, 1.0%) | 0 (of 21, 0.0%) |
| Kidney | 29 (of 2083, 1.4%) | 0 (of 19, 0.0%) |
| LCLs | 89 (of 2269, 3.9%) | 1 (of 31, 3.2%) |

Supplemental Table S10. Differences between tissues for QC metrics calculated by RNASeQC by Tukey HSD test. Difference in means between tissues and p-value for test shown below.

| Tissue Comparison | Intragenic.Rate | | Exonic.Rate | |
|-------------------|-----------------|-----------|-------------|----------|
| | Difference | Pvalue | Difference | Pvalue |
| Heart-Adipose | 0.0069 | 2.40E-03 | -0.0279 | 1.79E-01 |
| Kidney-Adipose | -0.0011 | -5.65E-03 | -0.0179 | 6.23E-01 |
| Kidney-Heart | -0.0080 | -1.25E-02 | 0.0100 | 9.34E-01 |
| Liver-Adipose | 0.0078 | 3.46E-03 | 0.0022 | 1.00E+00 |
| Liver-Heart | 0.0009 | -3.42E-03 | 0.0301 | 1.06E-01 |
| Liver-Kidney | 0.0089 | 4.53E-03 | 0.0201 | 4.85E-01 |
| LCL-Adipose | 0.0262 | 2.22E-02 | 0.1577 | 0.00E+00 |
| LCL-Heart | 0.0193 | 1.53E-02 | 0.1856 | 0.00E+00 |
| LCL-Kidney | 0.0273 | 2.33E-02 | 0.1756 | 0.00E+00 |
| LCL-Liver | -0.0183 | -2.22E-02 | -0.1555 | 0.00E+00 |

| Tissue Comparison | Intronic.Rate | | Intergenic.Rate | |
|-------------------|---------------|----------|-----------------|----------|
| | Difference | Pvalue | Difference | Pvalue |
| Heart-Adipose | 0.0348 | 2.08E-02 | -0.0071 | 2.22E-04 |
| Kidney-Adipose | 0.0168 | 5.83E-01 | 0.0011 | 9.65E-01 |
| Kidney-Heart | -0.0180 | 5.15E-01 | 0.0082 | 1.70E-05 |
| Liver-Adipose | 0.0056 | 9.86E-01 | -0.0078 | 2.63E-05 |
| Liver-Heart | -0.0291 | 6.68E-02 | -0.0006 | 9.95E-01 |
| Liver-Kidney | -0.0111 | 8.54E-01 | -0.0088 | 1.58E-06 |
| LCL-Adipose | -0.1315 | 0.00E+00 | -0.0264 | 0.00E+00 |
| LCL-Heart | -0.1663 | 0.00E+00 | -0.0193 | 0.00E+00 |
| LCL-Kidney | -0.1483 | 0.00E+00 | -0.0275 | 0.00E+00 |
| LCL-Liver | 0.1372 | 0.00E+00 | 0.0187 | 0.00E+00 |

| Tissue Comparison | Mean.Per.Base.Cov. | | Expression.Profiling.Efficiency | |
|-------------------|--------------------|----------|---------------------------------|----------|
| | Difference | Pvalue | Difference | Pvalue |
| Heart-Adipose | 0.1020 | 1.00E+00 | -0.0279 | 1.79E-01 |
| Kidney-Adipose | -11.5318 | 4.68E-03 | -0.0179 | 6.23E-01 |
| Kidney-Heart | -11.6338 | 4.21E-03 | 0.0100 | 9.34E-01 |
| Liver-Adipose | -15.1393 | 3.26E-05 | 0.0022 | 1.00E+00 |
| Liver-Heart | -15.2413 | 2.83E-05 | 0.0301 | 1.06E-01 |
| Liver-Kidney | -3.6074 | 7.84E-01 | 0.0201 | 4.85E-01 |
| LCL-Adipose | 31.4712 | 0.00E+00 | 0.1577 | 0.00E+00 |
| LCL-Heart | 31.3692 | 0.00E+00 | 0.1856 | 0.00E+00 |
| LCL-Kidney | 43.0030 | 0.00E+00 | 0.1756 | 0.00E+00 |
| LCL-Liver | -46.6105 | 0.00E+00 | -0.1555 | 0.00E+00 |

| Tissue Comparison | Fragment.Length.StdDev | | Fragment.Length.Mean | |
|-------------------|------------------------|----------|----------------------|----------|
| | Difference | Pvalue | Difference | Pvalue |
| Heart-Adipose | 4.4400 | 6.13E-01 | 2.9600 | 9.29E-01 |
| Kidney-Adipose | 0.5750 | 1.00E+00 | -5.6683 | 5.47E-01 |
| Kidney-Heart | -3.8650 | 7.35E-01 | -8.6283 | 1.44E-01 |
| Liver-Adipose | 2.3786 | 9.35E-01 | -5.5671 | 5.27E-01 |
| Liver-Heart | -2.0614 | 9.60E-01 | -8.5271 | 1.25E-01 |
| Liver-Kidney | 1.8036 | 9.77E-01 | 0.1012 | 1.00E+00 |
| LCL-Adipose | 79.3111 | 0.00E+00 | 51.6622 | 0.00E+00 |
| LCL-Heart | 74.8711 | 0.00E+00 | 48.7022 | 0.00E+00 |
| LCL-Kidney | 78.7361 | 0.00E+00 | 57.3306 | 0.00E+00 |
| LCL-Liver | -76.9325 | 0.00E+00 | -57.2294 | 0.00E+00 |

| Tissue Comparison | rRNA.rate | | 5prime100baseNorm | |
|-------------------|------------|----------|-------------------|----------|
| | Difference | Pvalue | Difference | Pvalue |
| Heart-Adipose | 0.0024 | 2.22E-03 | 0.0010 | 1.00E+00 |
| Kidney-Adipose | 0.0036 | 9.57E-07 | -0.0327 | 8.99E-03 |
| Kidney-Heart | 0.0012 | 3.25E-01 | -0.0337 | 6.44E-03 |
| Liver-Adipose | 0.0012 | 3.36E-01 | -0.0510 | 2.44E-06 |
| Liver-Heart | -0.0012 | 2.72E-01 | -0.0520 | 1.48E-06 |
| Liver-Kidney | -0.0025 | 1.26E-03 | -0.0183 | 3.11E-01 |
| LCL-Adipose | -0.0030 | 4.23E-06 | 0.0535 | 4.06E-08 |
| LCL-Heart | -0.0054 | 0.00E+00 | 0.0525 | 7.32E-08 |
| LCL-Kidney | -0.0066 | 0.00E+00 | 0.0862 | 0.00E+00 |
| LCL-Liver | 0.0042 | 2.99E-11 | -0.1045 | 0.00E+00 |

| Tissue Comparison | End.1.Mismatch.Rate | | End.2.Mismatch.Rate | |
|-------------------|---------------------|----------|---------------------|----------|
| | Difference | Pvalue | Difference | Pvalue |
| Heart-Adipose | -0.0005 | 8.54E-02 | -0.0008 | 6.51E-03 |
| Kidney-Adipose | -0.0004 | 2.37E-01 | -0.0009 | 3.35E-04 |
| Kidney-Heart | 0.0001 | 9.91E-01 | -0.0002 | 9.12E-01 |
| Liver-Adipose | -0.0004 | 3.17E-01 | -0.0012 | 7.75E-07 |
| Liver-Heart | 0.0001 | 9.53E-01 | -0.0005 | 2.17E-01 |
| Liver-Kidney | 0.0000 | 9.99E-01 | -0.0003 | 7.42E-01 |
| LCL-Adipose | 0.0003 | 4.87E-01 | 0.0004 | 2.66E-01 |
| LCL-Heart | 0.0008 | 1.29E-04 | 0.0011 | 2.26E-07 |
| LCL-Kidney | 0.0007 | 1.17E-03 | 0.0013 | 2.47E-09 |
| LCL-Liver | -0.0007 | 1.58E-03 | -0.0016 | 1.25E-13 |

| Tissue Comparison | Base.Mismatch.Rate | | End.1.Mapping.Rate | |
|-------------------|--------------------|----------|--------------------|----------|
| | Difference | Pvalue | Difference | Pvalue |
| Heart-Adipose | -0.0006 | 1.45E-02 | -0.0008 | 9.48E-01 |
| Kidney-Adipose | -0.0007 | 7.36E-03 | 0.0007 | 9.70E-01 |
| Kidney-Heart | 0.0000 | 9.99E-01 | 0.0014 | 6.56E-01 |
| Liver-Adipose | -0.0008 | 6.42E-04 | -0.0027 | 6.84E-02 |

| | | | | |
|--------------|---------|----------|---------|----------|
| Liver-Heart | -0.0002 | 9.25E-01 | -0.0019 | 3.29E-01 |
| Liver-Kidney | -0.0001 | 9.81E-01 | -0.0033 | 1.19E-02 |
| LCL-Adipose | 0.0003 | 3.06E-01 | 0.0035 | 1.83E-03 |
| LCL-Heart | 0.0010 | 1.30E-06 | 0.0043 | 7.22E-05 |
| LCL-Kidney | 0.0010 | 4.89E-07 | 0.0028 | 2.21E-02 |
| LCL-Liver | -0.0011 | 4.70E-09 | -0.0062 | 1.04E-09 |

| End.2.Mapping.Rate | | |
|--------------------|------------|----------|
| Tissue Comparison | Difference | Pvalue |
| Heart-Adipose | 0.0008 | 9.48E-01 |
| Kidney-Adipose | -0.0007 | 9.70E-01 |
| Kidney-Heart | -0.0014 | 6.56E-01 |
| Liver-Adipose | 0.0027 | 6.84E-02 |
| Liver-Heart | 0.0019 | 3.29E-01 |
| Liver-Kidney | 0.0033 | 1.19E-02 |
| LCL-Adipose | -0.0035 | 1.83E-03 |
| LCL-Heart | -0.0043 | 7.22E-05 |
| LCL-Kidney | -0.0028 | 2.21E-02 |
| LCL-Liver | 0.0062 | 1.04E-09 |

Supplemental Table S11. Housekeeping genes show low variability in FPKM values. (A) Between individuals: values shown are standard deviation of log₂(FPKM) values across individuals for each tissue. (B) Between tissues: values shown are the ratio of tissue-specific gene expression/geometric mean of expression across tissues. Housekeeping genes and definitions of variability from Eisenberg E, Levanon EY. Human housekeeping genes, revisited. Trends in genetics : TIG. 2013;29(10):569-74.

| A | C15orf24 | C1orf43 | CHMP2A | GPI | PSMB2 | PSMB4 | RAB7A | REEP5 | SNRPD3 | VCP | VPS29 |
|---------|----------|---------|--------|------|-------|-------|-------|-------|--------|------|-------|
| Kidney | 0.36 | 0.38 | 0.51 | 0.45 | 0.42 | 0.38 | 0.33 | 0.38 | 0.32 | 0.47 | 0.35 |
| Heart | 0.32 | 0.40 | 0.42 | 0.29 | 0.22 | 0.28 | 0.37 | 0.28 | 0.49 | 0.49 | 0.27 |
| Adipose | 0.22 | 0.19 | 0.22 | 0.22 | 0.14 | 0.19 | 0.17 | 0.14 | 0.30 | 0.23 | 0.15 |
| Liver | 0.23 | 0.35 | 0.35 | 0.45 | 0.27 | 0.34 | 0.32 | 0.21 | 0.28 | 0.49 | 0.19 |
| LCL | 0.15 | 0.15 | 0.28 | 0.32 | 0.17 | 0.28 | 0.25 | 0.34 | 0.26 | 0.29 | 0.16 |

| B | C15orf24 | C1orf43 | CHMP2A | GPI | PSMB2 | PSMB4 | RAB7A | REEP5 | SNRPD3 | VCP | VPS29 |
|---------|----------|---------|--------|------|-------|-------|-------|-------|--------|------|-------|
| Kidney | 0.53 | 0.56 | 1.03 | 0.35 | 0.59 | 0.88 | 0.90 | 0.66 | 0.57 | 0.68 | 0.26 |
| Heart | 0.79 | 1.07 | 0.85 | 1.17 | 0.58 | 0.66 | 0.97 | 1.24 | 0.79 | 1.14 | 0.82 |
| Adipose | 0.95 | 0.82 | 0.91 | 0.75 | 0.72 | 0.85 | 0.98 | 0.96 | 0.51 | 0.77 | 1.08 |
| Liver | 1.38 | 1.34 | 1.08 | 0.83 | 1.46 | 1.11 | 0.86 | 1.10 | 1.21 | 1.02 | 0.94 |
| LCL | 0.88 | 0.92 | 1.09 | 2.09 | 2.72 | 2.13 | 1.47 | 0.52 | 2.66 | 1.90 | 1.44 |

Supplemental Table S12. Reported are the number of pharmacogenes with a significantly differentially spliced event between tissues. Significant splicing events were determined by a Wilcoxon test on the 'percent spliced in' (PSI) values between two tissues (Benjamini-Hochberg corrected p-value <0.05) and the difference in median PSI between the tissues had to be >5. To be tested, an event must have a coverage of at least 10 reads/100bp in at least half the samples for each of the two tissues.

| Tissue 1 | Tissue 2 | Significantly differentially spliced in PGRN data | Also with sufficient coverage to be tested in GTEx data | Also significantly differentially spliced in GTEx data | % of tested in GTEx, sig in GTEx |
|-----------------|-----------------|--|--|---|---|
| Liver | Heart | 10 | 6 | 4 | 67% |
| Liver | Kidney* | 18 | 14 | 9 | 64% |
| Heart | Adipose | 12 | 8 | 4 | 50% |
| Liver | Adipose | 14 | 9 | 4 | 44% |
| Kidney* | Heart | 8 | 5 | 2 | 40% |
| Adipose | LCLs | 19 | 8 | 2 | 25% |
| Liver | LCLs | 14 | 5 | 1 | 20% |
| Kidney* | LCLs | 14 | 5 | 1 | 20% |
| Heart | LCLs | 16 | 7 | 1 | 14% |
| Kidney* | Adipose | 12 | 8 | 1 | 13% |
| | | 137 | 75 | 29 | 39% |

*GTEx has only 8 kidney samples, so the power to find significant differential splicing is reduced

Supplemental Table S13. Splice events in PGRN pharmacogenes with PSI (percent spliced in) ≥ 5 and coverage ≥ 1 read/100bp in at least one sample of one tissue and no coverage in any of the four other tissues. The ones checked in the GTEx data and observed to also only be present in one tissue had ≥ 1 read/100bp in at least one sample of one tissue and no coverage in any of the four other tissues. For a number of events, matching the events between the PGRN and GTEx runs of JuncBASE was non-trivial, possibly due to lack of read coverage or increased splicing complexity in the GTEx data.

| Tissue | Splice events observed in only one tissue in PGRN data | Checked in GTEx data | Also only observed in one tissue in GTEx | % of checked in GTEx, specific in GTEx |
|---------|--|----------------------|---|---|
| | Liver | 179 | 75 | 69 |
| Kidney | 80 | 36 | 32 | 89% |
| Heart | 96 | 25 | 16 | 64% |
| Adipose | 38 | 5 | 5 | 100% |
| LCLs | 63 | 16 | 12 | 75% |
| | 456 | 157 | 134 | 85% |